BYSI News and Press, BeyondSpring Inc. From 01/11/22

Resources to be Focused on Highest Value Business Activities 35% Reduction in Workforce in the U.S. Implemented to Preserve Long-Term Sustainability NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “...

- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant reduction of grade 4 neutropenia vs. docetaxel alone - IO combination advancement...

Adding plinabulin to a myelosuppressive chemotherapy regimen rapidly reversed (within 24 hours) chemotherapy-induced neutropenia and leukopenia in the PROTECTIVE-1 and -2 clinical studies, suggesting protection of the granulocyte-monocyte-progenitor stem cells as plinabulin’s mec...

The two posters will be presented on Friday, December 10, 2021 8:00 AM to 9:30 AM EST NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused ...

Gainers: Elevation Oncology (NASDAQ:ELEV) +25%. BeyondSpring (NASDAQ:BYSI) +21%. Nemaura Medical (NASDAQ:NMRD) +18%. Regencell Bioscience Holdings (NASDAQ:RGC) +17%. Novavax (NASDAQ:NVAX) +17%. Losers: HealthEquity (NASDAQ:HQY) -23%. Cumberland Pharmaceuticals (NASDAQ:CPIX) -21%. VY...

As scientists raced to uncover further details on the impact of the newly found Omicron variant on vaccine-driven immunity, COVID-19 antibody developers dominated best-performing healthcare stocks this week. While the sector became the fifth-worst performer in the S&P 500D dragged by the ...

One of the hottest trends in the stock market today has penny stock traders looking for short squeezes. Thanks to extensive breakouts from the likes of AMC Entertainment, GameStop, and plenty of others, the market metrics of this trend have led to huge making money potential. One of the...

After the FDA rejection of its combination therapy containing plinabulin for chemotherapy-induced neutropenia (CIN) led to a selloff on Wednesday, BeyondSpring (NASDAQ:BYSI) continues to trade lower with a ~5.0% decline in the pre-market. However, one Wall Street analyst remains hopeful ...

Gainers: Biofrontera (NASDAQ:BFRI) +36%. CF Acquisition (NASDAQ:CFVIU) +19%. Day One (NASDAQ:DAWN) +16%. Terns Pharmaceuticals (NASDAQ:TERN) +15%. Duluth Holdings (NASDAQ:DLTH) +15%. Snowflake (NYSE:SNOW) +14%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +14%. Express (NYSE:EXPR) +13%. Vor Biopharm...

Gainers: Biofrontera (NASDAQ:BFRI) +29%, Terns Pharmaceuticals (NASDAQ:TERN) +20%, Aurinia Pharmaceuticals (NASDAQ:AUPH) +17%, Atreca (NASDAQ:BCEL) +12%, 4D pharma (NASDAQ:LBPS) +9%. Losers: Context Therapeutics (NASDAQ:CNTX) -29%, 180 Life Sc...